Coherus Oncology Inc (CHRS)

R&D to Revenue

149.87%

Quarterly · Period ending:

CHRS logo

CHRS R&D to Revenue

Latest reported149.87%
CHRS Quarterly R&D/Revenue (1710.67% → 149.87%)
High-resolution chart · PNG

CHRS r&d to revenue history

Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.

Coherus Oncology Inc R&D to Revenue — Quarterly
Period endingR&D to Revenue
149.8707%
167.8473%
235.9429%
227.1714%
246.6355%
306.7509%
39.2195%
30.6271%
31.9611%
1,231.5425%
28.8099%
34.3941%
39.6263%
105.2966%
63.9928%
100.8454%
69.1776%
137.9306%
69.1854%
65.5552%
62.4876%
245.0707%
40.417%
34.2146%
19.2911%
28.4963%
28.2166%
19.3116%
22.6325%
50.6469%
0%
0%
0%
0%
0%
0%
2,473.1183%
33,400.6211%
6,991.7062%
39.6555%
465.9084%
528.4651%
504.344%
951.8348%
829.3621%
627.6592%
413.7841%
115.2255%
381.1682%
387.5417%
748.539%
975.0988%
1,768.6391%
1,710.6719%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.